Home
overview
A new and exciting era of medicine development has adorned with the onset of, predictive medicine, otherwise known as theranostics. The field of theranostics has lead the way for drug manufacturers to develop tomorrow’s medicines, which will be tailored to the individual. By enhancing the effectiveness of drugs: as a result it represents a commercial opportunity for both pharmaceutical and diagnostic industries.

With this knowledge in mind, our challenge at SMi was to assemble leaders in the fields of genomics, medicine, theranostics, and pharmaceutical development to offer an insight into the application of theranostics in medicine and to analyse the future of the industry.

Why must you attend this event?

This is your unique opportunity to meet senior industry executive and seek their advice and opinions. This comprehensive conference will also provide pertinent and up-to-date information on technologies underlying the theranostic industry and diagnostic capabilities. The commercial issues will also be discussed, with particular reference to the risks involved with drug discovery and dependence on alliance partners

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Chris Stanley

Chris Stanley, Senior Vice President, Cambridge Pharmaceutical Consultancy

9:10 IMPACT OF GENETICS AND GENOMICS ON DIAGNOSTICS AND THERAPEUTICS:

Prof Klaus Lindpaintner

Prof Klaus Lindpaintner, Vice President, Research & Director, Roche Genetics, F.Hoffman - La Roche

  • Opportunities: Better understanding of molecular pathology and drug action
  • Opportunities: Developing/choosing more effective medicines
  • Opportunities: Predisposition testing-targeted monitoring-early diagnosis - prevention
  • Challenges: An enormous amount of clinical data must be collected and analysed
  • Challenges: Dialogue with a concerned public
  • Challenges: Societal consensus on what use of information to sanction
    Challenges: Set appropriate, realistic expectations
  • 9:40 THE NEW INDUSTRY OF THERANOSTICS

    John Funkhouser

    John Funkhouser, President, Chief Exectutive Officer, Pharmanetics

  • Principles of theranostics
  • Implications for the pharmaceutical industry
  • Implications for the diagnostic industry
  • Potential to provide personalised medicine
  • Therapeutic areas & technological developments
  • New improvements for clinical trials success and product effectiveness
  • 10:20 IMPLICATIONS OF THERANOSTICS FOR DIAGNOSTIC AND PHARMACEUTICAL INDUSTRIES

    Dr Paul Kelly

    Dr Paul Kelly, President, Chief Exectutive Officer & Executive Director, Gemini Genomics

  • Current trends in drug development
  • How will theranostics improve drug design and diagnosis?
  • Adapting medicines
  • Novel diagnostics for the next generation
  • Theranostics - improving drugs and cutting costs?
  • Ambitions for the industry
  • 11:00 Morning Coffee

    11:20 PHARMACOGENOMICS IN THERANOSTICS

    Dr Mark Egerton

    Dr Mark Egerton, Vice President, Incyte Genomics

  • Application of pharmacogenomics
  • SNP mapping - its potentials and challenges
  • DNA probe arrays for pharmacogenomic discovery
  • Therapeutic management
  • Client implications
  • Future for pharmacogenomics
  • 12:00 THE PROMISE OF PROTEOMICS

    Dr Michael Shi

    Dr Michael Shi, Senior Director, Applied Genomics, Genometrix

  • Where the term proteomics came from
  • Haven’t we worked with proteins all along?
  • The position of proteomics today and tomorrow
  • Development of protein biochips
  • Commercialising a proteomic platform through corporate alliances applications
  • Market potential for proteomics
  • 12:40 Lunch

    14:00 IN-VITRO DIAGNOSTIC INDUSTRY

    Andrew Bufton

    Andrew Bufton, Director, External & Regulatory Affairs, Abbott Diagnostics

  • How innovative are these?
  • Do they have clinical and social utility?
  • Is there cost utility in prevention rather than cure?
  • Implications for design and reliability of tests?
  • New self-monitoring kits - the key to the future of diagnostics?
  • The demise of chronic disease?
  • 14:40 NOVEL DIAGNOSTIC TECHNOLOGIES FOR THERANOSTIC APPLICATIONS

    Chris Stanley

    Chris Stanley, Sr. Vice President, Cambridge Pharmaceutical Consultancy

  • Non-invasive measurement of glucose - faster, more accurate with guaranteed patient acceptance. But is it possible?
  • The point of care sector - providing advanced diagnostics in simple to use packages
  • Extreme sensitivity diagnostics - for analytes where the current state of the art label technologies lack the required performance
  • 15:20 Afternoon Tea

    15:40 PREDICTING CANCER

    Alexander Olek

    Alexander Olek, Chief Executive Officer, Epigenomics

  • An overview of the potentials regarding cancer diagnosis
  • DNA methylation patterns
  • Digitization
  • A genetic chip to diagnose disease?
  • Population targeting drugs?
  • A better future for patients
  • 16:20 NON-INVASIVE TESTING

    Dr Brent Norton

    Dr Brent Norton, President & Chief Executive Officer, IMI (International Medical Innovations)

  • The evolution of the skin cholesterol test
  • Practical use for the health system
  • Implications for patient therapies
  • How soon until a home version of cholesterol 1,2,3 test?
  • Risk analysis
  • Expectations for the future
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Drinks Reception for Delegates & Speakers

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Cecilia M. Brown

    Cecilia M. Brown, Marketing Manager, Cytyc UK

    9:10 MOLECULAR DIAGNOSTIC TESTING

    Dr Claire Allan

    Dr Claire Allan, Head, Molecular Diagnostics, GlaxoSmithKline

  • The current status of molecular diagnostic testing
  • Overview of current testing strategies
  • Molecular Diagnostics for Point Of Care Testing
  • Hurdles and limitations
  • Future prospects for molecular diagnostics
  • 9:40 NOVEL NUCLEIC ACID AMPLIFICATION ASSAYS

    Bruce Savage

    Bruce Savage, Managing Director, Cytocell

  • Automation, Point of care, quantitation
  • Applications: SNP detection, blood borne viruses, food microbiology,
  • m RNA expression, viral load measurement, antibiotic resistance genes
  • SMART and SPAR two new isothermal amplification technologies
  • Future trends
  • 10:20 PREDICTIVE MEDICINE WITH HIV

    Dr Bob Van Gemen

    Dr Bob Van Gemen, Chief Executive Officer, PrimaGen

  • Personalised treatment for Aids patients
  • HIV - 1 nucleic acids
  • Adverse affects of therapy
  • Challenges faced by new technology
  • The future for patients
  • 11:00 Morning Coffee

    11:20 NEW THERAPEUTIC OPPORTUNITIES

    Dr James Hawkins

    Dr James Hawkins, President, Hawkins & Associates

  • Foundations of theranostic testing
  • Applications for theranostics
  • Current state of genotype-based theranostics
  • Theranostics impact on diagnostics
  • The potential impact of theranostics on pharmaceutical industries
  • Business models that will help to maximise sharing of profits and risks
  • 12:00 INFECTIOUS DISEASE AND NEURODEGENERATIVE DISEASES

    Michel Baijot

    Michel Baijot, Vice President, Business Development, Innogenetics

  • Clinical needs
  • Trends in diagnostic and therapeutic programmes
  • Theranostic opportunities definition
  • Two examples of theranostic opportunities: Infectious diseases and neurodegenerative diseases
  • 12:40 Lunch

    13:40 DISEASE MANAGEMENT

    Dr Joanne Luciano

    Dr Joanne Luciano, President, Predictive Medicine, Inc., Harvard Medical School

  • Challenges in data
  • Challenges in the diagnosis
  • Computational opportunities: Selecting treatment for individual patients today
  • Informed patient monitoring and advancing clinical research
  • Selecting treatments for individual patients tomorrow
  • 14:20 MENTAL HEALTH DATA COLLECTION SOLUTIONS

    Dr Ron Calvanio

    Dr Ron Calvanio, Chief Scientific Officer, SymTrend Inc.

  • Overview
  • Symptom Reporting
  • Patient Monitoring
  • Treatment Evaluation
  • Care Planning
  • Examples of ECM solutions
  • 15:00 COMBINING WITH PREDICTIVE MEDICINE

    Bernard King

    Bernard King, President, Chief Executive Officer, Predict

  • Identifying drugs that will succeed
  • Screening patients in real time
  • Using artificial intelligence software
  • Implications of tailored therapies
  • Monitoring of drug safety
  • Integration: The way forward?
  • 15:40 Afternoon Tea

    16:00 WHO PAYS FOR WHAT TESTS?

    Dr David Robbins

    Dr David Robbins, Director of Microarray Applications, ViaLogy

  • The cost of tests affects whom?
  • Faster, smaller, trendier? Is that what the patient/consumer wants?
  • Great technology! Are the benefits worth the cost?
  • Great idea, you go first!
  • Who will pay to prove efficacy?
  • Better medicine or Big Brother?
  • 16:30 THE NEW PARADIGM OF PESONALISED MEDICINE

    Dr Eduardo Balbona

    Dr Eduardo Balbona, Chief Medical Officer, HealthScreen International

  • Evaluating risk before symptoms
  • Beyond population-based predictors
  • Consumer empowerment
  • Planning for health and productivity
  • The bio-informatics infrastructure of the future
  • The promise of the paradigm
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.